Genre
- Journal Article
In the present study, the expression and the regulation of ornithine decarboxylase (ODC) and S-adenosylmethionine decarboxylase (SAMDC) was examined in a series of oncogene transformed cell lines. The expression of both ODC and SAMDC was found to correlate with the nature of the oncogene expressed and with the resulting cellular phenotype expressed. This study demonstrates, for the first time, that the expression of both ODC and SAMDC increases as a function of cellular transformation and, in particular, as a function of malignant progression. Ras transformed cells were shown to express a unique regulatory mechanism whereby a co-ordinate up-regulation of the expression of both ODC and SAMDC occurs (via post-transcriptional stabilization of their mRNA transcripts) in the presence of protein synthesis inhibition. Altered expression (and regulation) of both ODC and SAMDC is suggested to constitute an important part of an altered growth regulatory program inherent to oncogene transformed cells, in particular, to transformed cells capable of malignant progression.
St Michaels Hosp, Dept Lab Med & Pathobiol, Toronto, ON M5B 1A6, Canada. Univ Toronto, Toronto, ON, Canada.; Hurta, RAR, St Michaels Hosp, Dept Lab Med & Pathobiol, 1-001,38 Shuter St,East Annex, Toronto, ON M5B 1A6, Canada.
DORDRECHT; SPUIBOULEVARD 50, PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS
KLUWER ACADEMIC PUBL
PT: J; CR: CHIAO PJ, 1991, ONCOGENE, V6, P713 DEBUSTROS A, 1985, J BIOL CHEM, V260, P98 EGAN SE, 1987, MOL CELL BIOL, V7, P830 EGAN SE, 1987, SCIENCE, V238, P202 EGAN SE, 1990, ANTICANCER RES, V10, P1391 FLAMIGNI F, 1999, BIOCHEM J 2, V341, P363 HEBY O, 1990, TRENDS BIOCHEM SCI, V15, P153 HOLLTA E, 1988, J BIOL CHEM, V263, P4500 HURTA RAR, 1996, J CELL BIOCHEM, V60, P572 JANNE J, 1991, ANN MED, V23, P241 MANNI A, 1997, INT J CANCER, V70, P175 MANSOUR SJ, 1994, SCIENCE, V265, P966 MARTON LJ, 1995, ANNU REV PHARMACOL, V35, P55 MCCANN PP, 1992, PHARMACOL THERAPEUT, V54, P195 MCNIGHT GS, 1992, FASEB J, V6, P2707 PAASINENSOHNS A, 1997, ONCOGENE, V15, P1953 PATEL AR, 1998, AM J PHYSIOL, P590 PEGG AE, 1982, AM J PHYSIOL, V243, P212 PEGG AE, 1986, BIOCHEM J, V234, P249 PEGG AE, 1988, CANCER RES, V48, P759 PEGG AE, 1992, PHARMACOL THERAPEUT, V56, P359 SHANTZ LM, 1998, CANCER RES, V58, P2748 SHAYOVITS A, 1995, BBA-MOL CELL RES, V1267, P107 SISTONEN L, 1987, EXP CELL RES, V168, P518 SUORSA A, 1992, BIOCHEM BIOPH RES CO, V184, P2 TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749 TRIMBLE WS, 1986, NATURE, V321, P782 TURLEY EA, 1991, J CELL BIOL, V112, P1041; NR: 28; TC: 4; J9: MOL CELL BIOCHEM; PG: 12; GA: 379KX
Source type: Electronic(1)
Language
- English
Subjects
- ENZYME TARGET
- susceptibility
- malignant progression
- C-HA-RAS
- POLYAMINES
- ornithine decarboxylase
- METASTATIC PHENOTYPE
- CELLS
- cellular transformation
- growth
- therapy
- S-adenosylmethionine decarboxylase
- Cell Biology
- altered expression